We have developed a differentiated pipeline of clinical-stage and preclinical drug candidates by leveraging our proprietary antibody discovery and development platforms.
MIL62 is a novel 3rd-generation anti-CD20 antibody and has been granted Breakthrough Therapy Designation (BTD) by NMPA in China for the treatment of primary membranous nephropathy (PMN). Additionally, its New Drug Application (NDA) for both the PMN and Neuromyelitis Optica Spectrum Disorders ( NMOSD ) indications have been accepted by the Center for Drug Evaluation (CDE) and subsequently included in the priority review procedure. It is expected to become the first approved targeted therapy for both PMN and NMOSD in China.
We strategically focus on the development of antibodies that stimulate the immune system to deplete target pathogenic cells, including three mechanisms: redirecting NK cells to kill target cells, redirecting T cells to kill target cells and infusing multi-specific antibody with immune stimulation activity. For this purpose, we have built proprietary antibody technology platforms, encompassing the process from antibody discovery to development. This enable us to design, evaluate, select and develop optimal drug candidates in an efficient and effective manner.
ADCC-enhanced Antibody Platform
Enhance NK-cell function through antibody glycosylation modification
Multi-specific Antibody Platform
Biology function-driven and structurally design
Antibody Discovery and Optimization Platform
Screen for candidates with high efficiency and low toxicity
